Currently Viewing
Adding surgery in metastatic kidney cancer could improve survival
March 21, 2014 – Elizabeth Whittington
The Little Couple has cancer
March 20, 2014 – Kathy LaTour
Increased screening leads to decrease in colorectal cancer
March 18, 2014 – Elizabeth Whittington
Lynch Syndrome Awareness Day: March 22
March 18, 2014 – Elizabeth Whittington
Healing Sounds of Music Therapy
March 17, 2014 – Amy Rushlow
Blood Pressure Meds Help Hypertensive Patients With Kidney Cancer
March 17, 2014
Is Immunotherapy the Key to Treating Brain Cancer?
March 07, 2014 – Susan Kreimer
Spreading the word about BRCA
March 05, 2014 – Guest
Personalized Medicine Revolution Gains Momentum
March 04, 2014 – Susan Jenks

Adding surgery in metastatic kidney cancer could improve survival

BY Elizabeth Whittington
PUBLISHED March 21, 2014
Elizabeth whittington blog image
One of the stories out of the ASCO Genitourinary Cancers Symposium earlier this year was that patients with metastatic kidney cancer may benefit from surgery in addition to biological treatments. Before targeted therapies, patients with metastatic renal cell carcinoma were treated with surgery and interferon. With the advent of targeted therapy, it's unknown whether surgery is still beneficial. The retrospective study examined patients treated with a targeted agent--most patients were treated with Sutent (sunitinib) or Nexavar (sorafenib). Because the study was not a randomized prospective study, patients chose whether to proceed with surgery, and about 60 percent elected to undergo a nephrectomy (surgical removal of the kidney). You can read the abstract here. Patients who had surgery lived longer than patients who did not have surgery (20.6 months versus 9.5 months). However, because those who elected to have surgery were in better health, researchers had to adjust the data, which ultimately came out to a 40 percent survival benefit. This effect was apparent in patients who had longer life expectancy and good prognostic factors. Researchers noted that patients who had poor prognostic factors, such as low blood counts, did not appear to benefit from surgery. Daniel Yick Chin Heng, presenting author of the study, said these results confirm a previous, but much smaller, study. "Cytoreductive nephrectomy may extend overall survival; however, not all patients should have it," he said. "Patients with a longer estimated survival can potentially stand to gain a lot more benefit from cytoreductive nephrectomy." Two phase 3 randomized studies will, hopefully, answer more questions in which patients would benefit from surgery.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In